Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H19N5 |
Molecular Weight | 293.3663 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
InChI
InChIKey=YBBLVLTVTVSKRW-UHFFFAOYSA-N
InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3
Anastrozole (marketed under the trade name Arimidex by AstraZeneca) is a drug indicated in the treatment of breast cancer in post-menopausal women. It is used both in adjuvant therapy (i.e. following surgery) and in metastatic breast cancer. It decreases the amount of estrogens that the body makes. Anastrozole belongs in the class of drugs known as aromatase inhibitors. It inhibits the enzyme aromatase, which is responsible for converting androgens (produced by women in the adrenal glands) to estrogens. The growth of many cancers of the breast is stimulated or maintained by estrogens. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme. Anastrozole is a selective non-steroidal aromatase inhibitor. It significantly lowers serum estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids or aldosterone.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1978 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19794821 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | ARIMIDEX Approved UseAnastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. Launch Date8.2002241E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
39.3 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19470631 |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ANASTROZOLE plasma | Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
648 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19470631 |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ANASTROZOLE plasma | Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: MALE food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
yes [Ki 10 uM] | ||||
yes [Ki 10 uM] | ||||
yes [Ki 8 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
low | ||||
low | ||||
low | ||||
major | ||||
major | ||||
minor | ||||
minor | ||||
minor | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Pure antiestrogens and breast cancer. | 2001 |
|
Aromatase inhibitors. | 2001 |
|
Breast cancer chemoprevention: beyond tamoxifen. | 2001 |
|
Estrogenic upregulation of DNA polymerase beta in oocytes of preovulatory ovine follicles. | 2001 Apr |
|
Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer. | 2001 Aug |
|
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. | 2001 Aug 3 |
|
Promising results for Arimidex and Femara. | 2001 Dec |
|
Future use of selective estrogen receptor modulators and aromatase inhibitors. | 2001 Dec |
|
The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients. | 2001 Dec |
|
A summary of second-line randomized studies of aromatase inhibitors. | 2001 Dec |
|
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. | 2001 Dec |
|
HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. | 2001 Dec 1 |
|
[Endometriosis and aromatase inhibitor]. | 2001 Jan |
|
Differential regulation of gonadotropin secretion by testosterone in the human male: absence of a negative feedback effect of testosterone on follicle-stimulating hormone secretion. | 2001 Jan |
|
Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. | 2001 Jan-Mar |
|
Endocrine therapy in the treatment of metastatic breast cancer. | 2001 Jun |
|
The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. | 2001 May |
|
Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention. | 2001 May |
|
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? | 2001 May 1 |
|
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? | 2001 May 1 |
|
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? | 2001 May 1 |
|
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? | 2001 May 1 |
|
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? | 2001 Nov |
|
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. | 2001 Nov 1 |
|
Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001. | 2001 Nov-Dec |
|
Aromatase inhibitors and inactivators in breast cancer. | 2001 Oct 20 |
|
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. | 2001 Sep |
|
Aromatase, aromatase inhibitors, and breast cancer. | 2001 Sep-Oct |
|
Finding the needle in the haystack: why high-throughput screening is good for your health. | 2002 |
|
Estrogen as therapy for breast cancer. | 2002 |
|
Recent advances in breast cancer (the Twenty-fourth San Antonio Breast Cancer Symposium, December, 2001). | 2002 |
|
Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. | 2002 |
|
Aromatase inhibitors continue their ATAC on tamoxifen. | 2002 |
|
Gateways to Clinical Trials. | 2002 Apr |
|
The oncology nurse's role in educating patients on endocrine therapy for metastatic breast cancer--focus on fulvestrant. | 2002 Apr |
|
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients. | 2002 Apr |
|
Effects of aromatase inhibition on in vitro follicle and oocyte development analyzed by early preantral mouse follicle culture. | 2002 Apr |
|
Fulvestrant. | 2002 Feb |
|
Hormones 'R' us. | 2002 Jan |
|
Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact. | 2002 Jul 1 |
|
Letrozole for the management of breast cancer. | 2002 Jun |
|
[Antiestrogen therapy in the treatment of breast neoplasms]. | 2002 Jun |
|
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. | 2002 Jun 22 |
|
Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer. | 2002 Jun 22 |
|
Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer. | 2002 Mar |
|
Aromatase inhibitors in breast cancer. | 2002 Mar |
|
Detection of aromatase inhibitors in vitro using rat ovary microsomes. | 2002 Mar 24 |
|
Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. | 2002 Mar-Apr |
|
Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy. | 2002 May |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25839436
Anastrozole, aromatase inhibitor was added at a concentration of 200 and 300 μg/mL to the endometrioma cells. The use of anastrozole significantly inhibited the growth of endometrioma cells, and estradiol secretion.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175563
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
||
|
WHO-VATC |
QL02BG03
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
||
|
WHO-ATC |
L02BG03
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
||
|
NCI_THESAURUS |
C2018
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
||
|
NDF-RT |
N0000175080
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
||
|
LIVERTOX |
NBK548189
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID9022607
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
DB01217
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
7462
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
2Z07MYW1AZ
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
5137
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
HH-1
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
2187
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
210
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
SUB05502MIG
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
120511-73-1
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
759855
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
2Z07MYW1AZ
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
CHEMBL1399
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
7274
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
84857
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | RxNorm | ||
|
M1889
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | Merck Index | ||
|
100000092332
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
719344
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
ANASTROZOLE
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
1034807
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
2704
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
C1607
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY | |||
|
C090450
Created by
admin on Wed Jul 05 23:22:18 UTC 2023 , Edited by admin on Wed Jul 05 23:22:18 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)